Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol Hydrochloride Solution for Inhalation in Adult Lower Respiratory Tract Infection with Viscous Sputum
CTR20221940Phase 3Completed
- Sponsor
- Shanxi Yanghe Pharmaceutical Technology
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambroxol in pulmonary infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumonia, acute bronchitis, sponsored by Shanxi Yanghe Pharmaceutical Technology. Started Aug 2022; status: completed.
02
Drugs
ambroxol
03
Conditions
pulmonary infectionchronic obstructive pulmonary disease (COPD)bronchiectasispneumoniaacute bronchitis
Beyond the preview
Go deeper on CTR20221940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221940.